Equities
  • Price (EUR)2.80
  • Today's Change0.000 / 0.00%
  • Shares traded403.00
  • 1 Year change-9.68%
  • Beta0.7689
Data delayed at least 15 minutes, as of Feb 11 2026 07:10 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Haohai Biological Technology Co Ltd is a China-based company mainly engaged in the production and sale of biological products, medical hyaluronic acid and intraocular lenses, research and development of bioengineering and pharmaceuticals, and provision of related services. The ophthalmology business has covered cataract treatment, myopia prevention and control, refractive correction, ocular surface medication, and optometry materials such as intraocular lenses and orthokeratology lenses. Medical beauty and wound care products include hyaluronic acid dermal fillers, hyaluronic acid gel for skin and mucosal superficial tissue supplementation. Orthopedic products include orthopedic joint cavity viscoelastic supplements and others. Anti-adhesion and hemostasis products include medical chitosan (for anti-adhesion), medical sodium hyaluronate gel and collagen sponge. The Company mainly conducts its businesses in domestic and foreign markets.

  • Revenue in HKD (TTM)2.91bn
  • Net income in HKD447.32m
  • Incorporated2007
  • Employees2.16k
  • Location
    Shanghai Haohai Biological Technology Co Ltd4F, No 2 Building, Alley 139Anshun Road, Changning DistrictSHANGHAI 200336ChinaCHN
  • Phone+86 2 152293555
  • Fax+86 2 152293558
  • Websitehttps://www.3healthcare.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.